Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HLX51 in Advanced Solid Tumors and Lymphoma
NCT05788107Phase 1Not yet recruiting
- Sponsor
- Henlius
- Start
- Jun 2024
- Primary completion
- May 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of HLX51 in solid tumor and lymphoma, sponsored by Henlius. Primary endpoints: Dose-Limiting Toxicity at 3 weeks and Maximum Tolerated Dose at 3 weeks. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
HLX51
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT05788107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05788107.